|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Stat Facts, . Thyroid Cancer
website. Available. https://seer.cancer.gov/statfacts/html/thyro.htmlSeptember
20–2018
|
|
3
|
Fagin JA and Wells SA Jr: Biologic and
clinical perspectives on thyroid cancer. N Engl J Med.
375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao L, Pang P, Zang L, Luo Y, Wang F,
Yang G, Du J, Wang X, Lyu Z, Dou J and Mu Y: Features and trends of
thyroid cancer in patients with thyroidectomies in Beijing, China
between 1994 and 2015: A retrospective study. BMJ Open.
9:e0233342019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cibas ES and Ali SZ: The 2017 bethesda
system for reporting thyroid cytopathology. Thyroid. 27:1341–1346.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jinih M, Foley N, Osho O, Houlihan L, Toor
AA, Khan JZ, Achakzai AA and Redmond HP: BRAFV600E
mutation as a predictor of thyroid malignancy in indeterminate
nodules: A systematic review and meta-analysis. Eur J Surg Oncol.
43:1219–1227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia Y, Yu Y, Li X, Wei S, Zheng X, Yang X,
Zhao J, Xia T and Gao M: Diagnostic value of B-RAF(V600E) in
difficult-to-diagnose thyroid nodules using fine-needle aspiration:
Systematic review and meta-analysis. Diagn Cytopathol. 42:94–101.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito Y, Miyauchi A, Inoue H, Fukushima M,
Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K and Miya
A: An observational trial for papillary thyroid microcarcinoma in
Japanese patients. World J Surg. 34:28–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong W, Horiuchi K, Tokumitsu H, Sakamoto
A, Noguchi E, Ueda Y and Okamoto T: Time-varying pattern of
mortality and recurrence from papillary thyroid cancer: Lessons
from a long-term follow-up. Thyroid. 29:802–808. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu DH, Zhang X, Wang H, Zhang L, Chen H,
Hu M, Dong Z, Zhu G, Qian Z, Fan J, et al: The essential role of
TNIK gene amplification in gastric cancer growth. Oncogenesis.
2:e892014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Torres-Ayuso P, An E, Nyswaner KM, Bensen
RC, Ritt DA, Specht SI, Das S, Andresson T, Cachau RE, Liang RJ, et
al: TNIK is a therapeutic target in lung squamous cell carcinoma
and regulates FAK activation through merlin. Cancer Discov.
11:1411–1423. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mahmoudi T, Li VS, Ng SS, Taouatas N,
Vries RG, Mohammed S, Heck AJ and Clevers H: The kinase TNIK is an
essential activator of Wnt target genes. EMBO J. 28:3329–3340.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shitashige M, Satow R, Honda K, Ono M,
Hirohashi S and Yamada T: Regulation of Wnt signaling by the
nuclear pore complex. Gastroenterology. 134:1961–1971. 1971.e1–e4.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gui J, Yang B, Wu J and Zhou X: Enormous
influence of TNIK knockdown on intracellular signals and cell
survival. Hum Cell. 24:121–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shitashige M, Satow R, Jigami T, Aoki K,
Honda K, Shibata T, Ono M, Hirohashi S and Yamada T: Traf2- and
Nck-interacting kinase is essential for Wnt signaling and
colorectal cancer growth. Cancer Res. 70:5024–5033. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin J, Jung HY, Wang Y, Xie J, Yeom YI,
Jang JJ and Lee KB: Nuclear expression of phosphorylated TRAF2- and
NCK-interacting kinase in hepatocellular carcinoma is associated
with poor prognosis. Pathol Res Pract. 210:621–627. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahashi H, Ishikawa T, Ishiguro M,
Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H,
Uetake H and Sugihara K: Prognostic significance of Traf2- and
Nck-interacting kinase (TNIK) in colorectal cancer. BMC Cancer.
15:7942015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Jiang H, Qin M, Su X, Cao Z and
Wang J: TNIK serves as a novel biomarker associated with poor
prognosis in patients with pancreatic cancer. Tumour Biol.
37:1035–1040. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fleuren EDG, Zhang L, Wu J and Daly RJ:
The kinome ‘at large’ in cancer. Nat Rev Cancer. 16:83–98. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masuda M, Uno Y, Ohbayashi N, Ohata H,
Mimata A, Kukimoto-Niino M, Moriyama H, Kashimoto S, Inoue T, Goto
N, et al: TNIK inhibition abrogates colorectal cancer stemness. Nat
Commun. 7:125862016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sekita T, Yamada T, Kobayashi E, Yoshida
A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, et
al: Feasibility of targeting Traf2-and-Nck-interacting kinase in
synovial sarcoma. Cancers (Basel). 12:12582020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sugano T, Masuda M, Takeshita F, Motoi N,
Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, et al:
Pharmacological blockage of transforming growth factor-β signalling
by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J
Cancer. 124:228–236. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirozane T, Masuda M, Sugano T, Sekita T,
Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, et al:
Direct conversion of osteosarcoma to adipocytes by targeting TNIK.
JCI Insight. 6:e1372452021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee RS, Zhang L, Berger A, Lawrence MG,
Song J, Niranjan B, Davies RG, Lister NL, Sandhu SK, Rubin MA, et
al: Characterization of the ERG-regulated kinome in prostate cancer
identifies TNIK as a potential therapeutic target. Neoplasia.
21:389–400. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sato K, Padgaonkar AA, Baker SJ, Cosenza
SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A,
Port ER, Aggarwal AK, et al: Simultaneous CK2/TNIK/DYRK1 inhibition
by 108600 suppresses triple negative breast cancer stem cells and
chemotherapy-resistant disease. Nat Commun. 12:46712021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yokoyama Y, Sato S, Futagami M, Fukushi Y,
Sakamoto T, Umemoto M and Saito Y: Prognostic significance of
vascular endothelial growth factor and its receptors in endometrial
carcinoma. Gynecol Oncol. 77:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Joseph KR, Edirimanne S and Eslick GD:
Multifocality as a prognostic factor in thyroid cancer: A
meta-analysis. Int J Surg. 50:121–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanks SK, Quinn AM and Hunter T: The
protein kinase family: Conserved features and deduced phylogeny of
the catalytic domains. Science. 241:42–52. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hunter T: Protein kinase classification.
Methods Enzymol. 200:3–37. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wissing J, Jänsch L, Nimtz M, Dieterich G,
Hornberger R, Kéri G, Wehland J and Daub H: Proteomics analysis of
protein kinases by target class-selective prefractionation and
tandem mass spectrometry. Mol Cell Proteomics. 6:537–547. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu R, Gao Q, Foltz SM, Fowles JS, Yao L,
Wang JT, Cao S, Sun H, Wendl MC, Sethuraman S, et al: Co-evolution
of tumor and immune cells during progression of multiple myeloma.
Nat Commun. 12:25592021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fukushima T, Suzuki S, Mashiko M, Ohtake
T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K and Takenoshita S:
BRAF mutations in papillary carcinomas of the thyroid. Oncogene.
22:6455–6457. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
36
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
